查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1818080

全球抗癌藥物市場：預測（至 2032 年）－按藥物類別、治療類型、癌症類型、劑型、通路和地區進行分析

Oncology Drugs Market Forecasts to 2032 - Global Analysis By Drug Class, Therapy Type, Cancer Type, Dosage Form, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球抗癌藥物市場預計在 2025 年達到 2,589.8 億美元，到 2032 年將達到 6,207 億美元，預測期內的複合年成長率為 13.3%。

抗癌藥物是透過清除惡性細胞、抑制其發展和預防轉移來對抗各種癌症的專門藥物。這類藥物包括化療、免疫療法、荷爾蒙療法和標靶治療。其主要目標是延長患者的生存期、緩解症狀並改善生活品質。抗癌藥物在改善癌症治療患者的生存期、控制症狀和提高生活品質方面發揮著重要作用。

根據諾華公司2020年發布的年度報告，抗癌藥物部門的成長率較2019年放緩，為2.4%。

標靶治療需求不斷成長

由於標靶治療的應用日益廣泛，抗癌藥物正在經歷強勁成長。與傳統治療相比，標靶治療具有更高的療效和更少的副作用。這些治療方法旨在抑制參與癌症進展的特定分子，從而實現更精確和個人化的治療方法。癌症發病率的上升和診斷能力的提高正在推動對這些先進療法的需求。製藥公司正在大力投資研發針對多種癌症類型的新型標靶藥物。此外，監管機構正在簡化突破性治療方法的核准途徑，進一步加速了市場發展勢頭。隨著臨床醫師和患者意識的提高，標靶治療正成為現代腫瘤治療的核心部分。

嚴格的監管流程

藥物開發商必須滿足嚴格的臨床試驗要求、安全性評估和上市後監管要求。這些流程往往會延遲產品上市並增加開發成本，尤其對於規模較小的生技公司。全球監管標準的協調仍然是一項挑戰，使得國際市場准入更加複雜。此外，數據透明度和患者知情同意的合規框架不斷發展，也帶來了沉重的行政負擔。因此，許多公司採取了謹慎的策略，選擇分階段試驗和區域推廣來降低風險。

精準醫療和個人化治療

隨著治療方案越來越貼合個別基因特徵，精準醫療的轉變正為腫瘤學開闢新的成長途徑。基因組學、生物標記識別和伴隨診斷的進步使得更精準地標靶化癌細胞成為可能。這種方法在增強治療效果的同時，最大限度地減少了副作用，對醫護人員和患者都極具吸引力。政府和醫療體係也透過資金投入和基礎設施升級來支持精準腫瘤學。隨著個人化醫療成為主流，它有望重新定義癌症治療模式，並推動市場持續擴張。

專利到期和生物相似藥競爭

當重磅抗癌學名藥和生物相似藥便會進入市場，侵蝕原廠公司的收益。雖然這些替代方案具有成本效益，但它們也增加了定價壓力並削弱了品牌忠誠度。生物相似藥的監管核准正在簡化，加速了其在主要市場的普及。此外，支付系統越來越傾向於生物相似藥以降低醫療成本，這進一步挑戰了品牌藥的銷售。如果沒有持續的創新和生命週期管理，現有企業就有可能將市場佔有率拱手讓給更敏捷的競爭對手。

COVID-19的影響

COVID-19疫情擾亂了腫瘤科診療流程，延誤了診斷、治療和臨床試驗。封鎖措施以及為應對疫情而進行的資源重新分配，給腫瘤科室帶來了壓力，並減少了患者的就診機會。然而，這場危機加速了數位醫療的普及，包括遠距腫瘤診療和遠端監控解決方案。製藥公司透過數位化臨床實驗通訊協定並利用虛擬平台與病人參與，適應了這種變化。供應鏈中斷暫時影響了藥品供應，並促使企業採取多元化策略。疫情過後，重點已轉向建構具有韌性的腫瘤診療系統，以抵禦未來的中斷，同時維持診療的連續性。

預測期內標靶治療藥物市場規模預計將達到最大

標靶治療領域預計將在預測期內佔據最大的市場佔有率，這得益於其卓越的療效和特異性。由於毒性降低和患者預後改善，這些藥物正逐漸成為傳統化療的首選。越來越多的臨床證據和監管支持正在推動標靶治療在多種癌症類型中更廣泛的應用。製藥公司正優先考慮該領域的產品線開發，目前已有多種藥物處於後期臨床試驗階段。生物標記和伴隨診斷的整合正在提高治療精準度，並支持其廣泛應用。標靶治療成為標準治療方案，其很可能在標靶治療治療領域佔據主導地位。

預計線上藥局市場在預測期內將以最高的複合年成長率成長

預計線上藥局領域將在預測期內實現最高成長率，這得益於消費者對數位醫療解決方案日益成長的偏好。宅配的便利性，尤其是在慢性癌症治療領域，正在推動線上藥局的普及。新冠疫情加速了醫藥電商化進程，越來越多的抗癌藥物可以透過安全平台取得。監管機構正在更新相關框架，以支援專科藥物的安全線上配藥。製藥公司與數位醫療服務提供者之間的夥伴關係正在擴大藥局的可及性，並提高患者的依從性。隨著數位基礎設施的加強，線上藥局有望成為腫瘤領域的關鍵分銷管道。

比最大的地區

由於癌症發病率上升和醫療基礎設施不斷擴張，預計亞太地區將在預測期內佔據最大市場佔有率。中國、印度和日本等國正大力投資腫瘤學研究、治療中心和藥物供應。政府津貼癌症治療和改善早期檢測的措施正在推動需求成長。快速的都市化和生活方式的改變導致癌症發病率上升，並刺激了藥品消費的成長。本地生產和有利的監管改革正在吸引全球參與者進入該地區。隨著認知度和價格分佈的提高，亞太地區預計將在抗癌藥物市場保持主導地位。

複合年成長率最高的地區：

由於強大的創新管道和支持性的報銷政策，預計北美地區在預測期內的複合年成長率最高。美國和加拿大在精準腫瘤學研究方面處於領先地位，基因組檢測和標靶治療被廣泛採用。聯邦資金和私人投資正在推動免疫腫瘤學和細胞療法的研發。 FDA 等監管機構正在簡化突破性抗癌藥物的核准流程。人工智慧和巨量資料在癌症研究中的整合正在加速藥物研發和個人化治療。

免費客製化服務

此報告的訂閱者可以從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 市場機遇
  • 威脅
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

第5章全球抗癌藥物市場（依藥物類別）

  • 細胞毒性藥物
  • 標靶治療藥物
  • 荷爾蒙療法藥物
  • 免疫療法
  • 其他藥物類別

第6章全球抗癌藥物市場依治療類型

  • 化療
  • 標靶治療
  • 免疫療法
  • 聯合治療
  • 荷爾蒙療法

第7章全球抗癌藥物市場（依癌症類型）

  • 肺癌
  • 膀胱癌
  • 乳癌
  • 甲狀腺癌
  • 大腸直腸癌
  • 子宮頸癌
  • 攝護腺癌
  • 多發性骨髓瘤
  • 胃癌
  • 肝癌
  • 其他罕見癌症

第8章全球抗癌藥物市場（按劑型）

  • 固體的
  • 液體
  • 注射

9. 全球抗癌藥物市場（依分銷管道）

  • 醫院藥房
  • 專科診所
  • 零售藥局
  • 網路藥局

第 10 章全球抗癌藥物市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Merck & Co.
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • AstraZeneca
  • Daiichi Sankyo
  • Johnson & Johnson
  • Sanofi
  • Roche
  • AbbVie
  • Pfizer
  • Astellas Pharma
  • Novartis
  • Amgen
  • Eli Lilly
Product Code: SMRC31043

According to Stratistics MRC, the Global Oncology Drugs Market is accounted for $258.98 billion in 2025 and is expected to reach $620.70 billion by 2032 growing at a CAGR of 13.3% during the forecast period. Oncology drugs are specialized medicines created to combat various forms of cancer by eliminating malignant cells, controlling their development, or blocking their metastasis. This category covers chemotherapy, immunotherapy, hormone therapy, and targeted treatments. Their primary purpose is to extend patient survival, ease symptoms, and improve quality of life. Oncology drugs play a crucial role in improving patient survival rates, managing symptoms, and enhancing quality of life for individuals undergoing cancer treatment.

According to the annual report of Novartis AG published in 2020, the oncology drugs segment witnessed a slow growth of 2.4% as compared to 2019.

Market Dynamics:

Driver:

Growing demand for targeted therapies

The oncology drugs is witnessing robust growth due to increasing adoption of targeted therapies that offer higher efficacy and fewer side effects compared to traditional treatments. These therapies are designed to interfere with specific molecules involved in cancer progression, making them more precise and personalized. Rising cancer prevalence and improved diagnostic capabilities are accelerating demand for such advanced treatments. Pharmaceutical companies are investing heavily in R&D to develop novel targeted agents across multiple cancer types. Additionally, regulatory bodies are streamlining approval pathways for breakthrough therapies, further boosting market momentum. As awareness grows among clinicians and patients, targeted therapies are becoming central to modern oncology care.

Restraint:

Stringent regulatory processes

Drug developers must navigate rigorous clinical trial requirements, safety evaluations, and post-marketing surveillance mandates. These processes often delay product launches and increase development costs, especially for smaller biotech firms. Harmonizing global regulatory standards remains a challenge, complicating international market entry. Moreover, evolving compliance frameworks around data transparency and patient consent add layers of administrative burden. As a result, many companies adopt cautious strategies, opting for phased trials and regional rollouts to mitigate risk.

Opportunity:

Precision medicine and personalized therapies

The shift toward precision medicine is unlocking new growth avenues in oncology, as treatments are increasingly tailored to individual genetic profiles. Advances in genomics, biomarker identification, and companion diagnostics are enabling more accurate targeting of cancer cells. This approach enhances treatment outcomes while minimizing adverse effects, making it highly attractive to both providers and patients. Governments and healthcare systems are also supporting precision oncology through funding and infrastructure upgrades. As personalized therapies become mainstream, they are expected to redefine cancer treatment paradigms and drive sustained market expansion.

Threat:

Patent expirations and biosimilar competition

As patents on blockbuster cancer drugs expire, generic and biosimilar versions enter the market, eroding revenue for originator companies. These alternatives, while cost-effective, intensify pricing pressure and reduce brand loyalty. Regulatory approvals for biosimilars are becoming more streamlined, accelerating their adoption across key markets. Additionally, payer systems are increasingly favouring biosimilars to reduce healthcare costs, further challenging branded drug sales. Without continuous innovation and lifecycle management, established players risk losing market share to agile competitors.

Covid-19 Impact

The COVID-19 pandemic disrupted oncology care pathways, delaying diagnoses, treatments, and clinical trials. Lockdowns and resource reallocation toward pandemic response strained oncology departments and reduced patient access. However, the crisis also accelerated digital health adoption, including tele-oncology and remote monitoring solutions. Pharma companies adapted by digitizing trial protocols and leveraging virtual platforms for patient engagement. Supply chain interruptions temporarily affected drug availability, prompting diversification strategies. Post-pandemic, the focus has shifted toward building resilient oncology systems that can withstand future disruptions while maintaining continuity of care.

The targeted therapy drugs segment is expected to be the largest during the forecast period

The targeted therapy drugs segment is expected to account for the largest market share during the forecast period, driven by their superior efficacy and specificity. These drugs are increasingly preferred over conventional chemotherapy due to reduced toxicity and better patient outcomes. Growing clinical evidence and regulatory support are encouraging broader adoption across multiple cancer types. Pharmaceutical firms are prioritizing pipeline development in this segment, with numerous agents in late-stage trials. Integration of biomarkers and companion diagnostics is enhancing treatment precision and boosting uptake. As targeted therapies become standard of care, they will continue to dominate the oncology drug landscape.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online pharmacies segment is predicted to witness the highest growth rate, due to rising consumer preference for digital healthcare solutions. The convenience of home delivery, especially for chronic cancer treatments, is driving adoption. COVID-19 accelerated the shift toward e-commerce in pharmaceuticals, with oncology drugs increasingly available through secure platforms. Regulatory bodies are updating frameworks to support safe online dispensing of specialty medications. Partnerships between pharma companies and digital health providers are expanding access and improving patient adherence. As digital infrastructure strengthens, online pharmacies are poised to become a key distribution channel in oncology.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cancer incidence and expanding healthcare infrastructure. Countries like China, India, and Japan are investing heavily in oncology research, treatment centres, and drug accessibility. Government initiatives to subsidize cancer care and improve early detection are boosting demand. Rapid urbanization and lifestyle changes are contributing to higher cancer prevalence, prompting increased pharmaceutical consumption. Local manufacturing and favourable regulatory reforms are attracting global players to the region. As awareness and affordability improve, Asia Pacific will remain a dominant force in the oncology drugs market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong innovation pipelines and supportive reimbursement policies. The U.S. and Canada are leading in precision oncology, with widespread adoption of genomic testing and targeted therapies. Federal funding and private investment are fueling R&D in immuno-oncology and cell-based treatments. Regulatory agencies like the FDA are streamlining approval processes for breakthrough cancer drugs. Integration of AI and big data in oncology research is accelerating drug discovery and personalized care.

Key players in the market

Some of the key players profiled in the Oncology Drugs Market include Merck & Co., Gilead Sciences, Bristol-Myers Squibb, Takeda Pharmaceutical, AstraZeneca, Daiichi Sankyo, Johnson & Johnson, Sanofi, Roche, AbbVie, Pfizer, Astellas Pharma, Novartis, Amgen, and Eli Lilly.

Key Developments:

In September 2025, Gilead Sciences, Inc. announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief to deliver lenacapavir Gilead's twice-yearly injectable HIV-1 capsid inhibitor for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance access to lenacapavir for PrEP for up to two million people over three years in countries supported by both organizations.

In July 2025, Merck and Verona Pharma plc announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

Drug Classes Covered:

  • Cytotoxic Drugs
  • Targeted Therapy Drugs
  • Hormonal Therapy Drugs
  • Immunotherapy Drugs
  • Other Drug Classes

Therapy Types Covered:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Combination Therapies
  • Hormonal Therapy

Cancer Types Covered:

  • Lung Cancer
  • Bladder Cancer
  • Breast Cancer
  • Thyroid Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Prostate Cancer
  • Multiple Myeloma
  • Stomach Cancer
  • Liver Cancer
  • Other Rare Cancers

Dosage Forms Covered:

  • Solid
  • Liquid
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Oncology Drugs Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Cytotoxic Drugs
  • 5.3 Targeted Therapy Drugs
  • 5.4 Hormonal Therapy Drugs
  • 5.5 Immunotherapy Drugs
  • 5.6 Other Drug Classes

6 Global Oncology Drugs Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Chemotherapy
  • 6.3 Targeted Therapy
  • 6.4 Immunotherapy
  • 6.5 Combination Therapies
  • 6.6 Hormonal Therapy

7 Global Oncology Drugs Market, By Cancer Type

  • 7.1 Introduction
  • 7.2 Lung Cancer
  • 7.3 Bladder Cancer
  • 7.4 Breast Cancer
  • 7.5 Thyroid Cancer
  • 7.6 Colorectal Cancer
  • 7.7 Cervical Cancer
  • 7.8 Prostate Cancer
  • 7.9 Multiple Myeloma
  • 7.10 Stomach Cancer
  • 7.11 Liver Cancer
  • 7.12 Other Rare Cancers

8 Global Oncology Drugs Market, By Dosage Form

  • 8.1 Introduction
  • 8.2 Solid
  • 8.3 Liquid
  • 8.4 Injectable

9 Global Oncology Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Specialty Clinics
  • 9.4 Retail Pharmacies
  • 9.5 Online Pharmacies

10 Global Oncology Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Merck & Co.
  • 12.2 Gilead Sciences
  • 12.3 Bristol-Myers Squibb
  • 12.4 Takeda Pharmaceutical
  • 12.5 AstraZeneca
  • 12.6 Daiichi Sankyo
  • 12.7 Johnson & Johnson
  • 12.8 Sanofi
  • 12.9 Roche
  • 12.10 AbbVie
  • 12.11 Pfizer
  • 12.12 Astellas Pharma
  • 12.12 Novartis
  • 12.14 Amgen
  • 12.15 Eli Lilly

List of Tables

  • Table 1 Global Oncology Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Oncology Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Oncology Drugs Market Outlook, By Cytotoxic Drugs (2024-2032) ($MN)
  • Table 4 Global Oncology Drugs Market Outlook, By Targeted Therapy Drugs (2024-2032) ($MN)
  • Table 5 Global Oncology Drugs Market Outlook, By Hormonal Therapy Drugs (2024-2032) ($MN)
  • Table 6 Global Oncology Drugs Market Outlook, By Immunotherapy Drugs (2024-2032) ($MN)
  • Table 7 Global Oncology Drugs Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 8 Global Oncology Drugs Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 9 Global Oncology Drugs Market Outlook, By Chemotherapy (2024-2032) ($MN)
  • Table 10 Global Oncology Drugs Market Outlook, By Targeted Therapy (2024-2032) ($MN)
  • Table 11 Global Oncology Drugs Market Outlook, By Immunotherapy (2024-2032) ($MN)
  • Table 12 Global Oncology Drugs Market Outlook, By Combination Therapies (2024-2032) ($MN)
  • Table 13 Global Oncology Drugs Market Outlook, By Hormonal Therapy (2024-2032) ($MN)
  • Table 14 Global Oncology Drugs Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 15 Global Oncology Drugs Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 16 Global Oncology Drugs Market Outlook, By Bladder Cancer (2024-2032) ($MN)
  • Table 17 Global Oncology Drugs Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 18 Global Oncology Drugs Market Outlook, By Thyroid Cancer (2024-2032) ($MN)
  • Table 19 Global Oncology Drugs Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 20 Global Oncology Drugs Market Outlook, By Cervical Cancer (2024-2032) ($MN)
  • Table 21 Global Oncology Drugs Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 22 Global Oncology Drugs Market Outlook, By Multiple Myeloma (2024-2032) ($MN)
  • Table 23 Global Oncology Drugs Market Outlook, By Stomach Cancer (2024-2032) ($MN)
  • Table 24 Global Oncology Drugs Market Outlook, By Liver Cancer (2024-2032) ($MN)
  • Table 25 Global Oncology Drugs Market Outlook, By Other Rare Cancers (2024-2032) ($MN)
  • Table 26 Global Oncology Drugs Market Outlook, By Dosage Form (2024-2032) ($MN)
  • Table 27 Global Oncology Drugs Market Outlook, By Solid (2024-2032) ($MN)
  • Table 28 Global Oncology Drugs Market Outlook, By Liquid (2024-2032) ($MN)
  • Table 29 Global Oncology Drugs Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 30 Global Oncology Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 31 Global Oncology Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 32 Global Oncology Drugs Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 33 Global Oncology Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 34 Global Oncology Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.